表紙
市場調査レポート

急性骨髄性白血病(AML、急性骨髄芽球性白血病) - パイプラインレビュー

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 232771
出版日 ページ情報 英文 1249 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
急性骨髄性白血病(AML、急性骨髄芽球性白血病) - パイプラインレビュー Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015
出版日: 2015年08月19日 ページ情報: 英文 1249 Pages
概要

急性骨髄性白血病(AML)は急性骨髄芽球性白血病としても知られており、血液および骨髄を侵す疾患です。未熟な白血球が骨髄に蓄積することによって、正常な血液細胞の生成が妨げられてしまいます。これらの細胞はその後血液の中に入り込み、全身に広がります。 症侯は、疲労感、熱、出血、呼吸困難、体重の減少などが見られます。関係する素因としては、放射線や化学物質に曝されたり喫煙などが挙げられます。ある特定の血液疾患の結果としてこのAML以外の疾患も発症することがあります。治療は化学療法や輸血、移植、薬物療法などで管理します。

当レポートでは、急性骨髄性白血病(AML)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

急性骨髄性白血病(AML、急性骨髄芽球性白血病)概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7054IDB

Summary

Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015', provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview
  • Therapeutics Development
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
  • Drug Profiles
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Recent Pipeline Updates
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1
  • Appendix 1

List of Tables

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2015
  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Development by Companies, H2 2015 (Contd..10)
  • Number of Products under Development by Companies, H2 2015 (Contd..11)
  • Number of Products under Development by Companies, H2 2015 (Contd..12)
  • Number of Products under Development by Companies, H2 2015 (Contd..13)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Development by Companies, H2 2015 (Contd..13)
  • Products under Development by Companies, H2 2015 (Contd..14)
  • Products under Development by Companies, H2 2015 (Contd..15)
  • Products under Development by Companies, H2 2015 (Contd..16)
  • Products under Development by Companies, H2 2015 (Contd..17)
  • Products under Development by Companies, H2 2015 (Contd..18)
  • Products under Development by Companies, H2 2015 (Contd..19)
  • Products under Development by Companies, H2 2015 (Contd..20)
  • Products under Development by Companies, H2 2015 (Contd..21)
  • Products under Development by Companies, H2 2015 (Contd..22)
  • Products under Development by Companies, H2 2015 (Contd..23)
  • Products under Development by Companies, H2 2015 (Contd..24)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories, LLC, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics B.V., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Akinion Pharmaceuticals AB, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascenta Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BIND Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioInvent International AB, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx, Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis S.A., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Clevexel Pharma SAS, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CureTech Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime B.V., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Debiopharm International S.A., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DiNonA Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Egenix, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem, S.L., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics S.A., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ignyta, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Juno Therapeutics Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corporation, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kinex Pharmaceuticals, LLC, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Komipharm International Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MedImmune, LLC, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co., Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus B.V., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mirna Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MolMed S.p.A., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NantKwest, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Neumedicines Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Limited, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OXiGENE, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharma Mar, S.A., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmacyclics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen S.p.A., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sellas Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Senhwa Biosciences, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sentinel Oncology Limited, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sorrento Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SpectraMab GmbH, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syros Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tautatis Incorporated, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Theravectys SA, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trillium Therapeutics Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Verastem, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Vichem Chemie Research Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Viralytics Ltd., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xencor, Inc., H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xenetic Biosciences plc, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics - Recent Pipeline Updates, H2 2015
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..1), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..2), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..3), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..4), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..5), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..6), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..7), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..8), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..9), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..10), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..11), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..1), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..2), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..3), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..4), H2 2015 1
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..5), H2 2015

List of Figures

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2015
  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top